Year 2017 / Volume 109 / Number 12
Digestive Diseases Image
Immune mediated colitis caused by lung cancer treatment with atezolizumab

863-864

DOI: 10.17235/reed.2017.5060/2017

Santiago González Vázquez, Susana de la Riva Onandía, José Ignacio Echeveste, Miguel Muñoz Navas,

Abstract
Atezolizumab is an IgG1 isotype monoclonal antibody against the protein programmed cell death-ligand 1 (PD- L1). PD-L1 may be highly expressed in some tumors and is believed to inhibit immune cells that recognize and attack tumor cells. Inhibition of PD-L1 can remove its inhibitory effect and provoke an anti-tumor response. In October 2016, the Food and Drugs Administration (FDA) approved atezolizumab for the treatment of patients with metastatic non-small cell lung cancer after disease progression during or following platinum based chemotherapy. We present the case of a 43-year-old male with stage IV lung adenocarcinoma in progression, despite standard chemotherapy.
Share Button
New comment
Comments
No comments for this article
References
Abdel-Rahman O, ElHalawani H, Fouad M. Risk of gastrointestinal complications in cancer patients treated with immune checkpoint inhibitors: a meta-analysis. Immunotherapy. 2015;7(11):1213-27.
De Velasco G, Je Y, Bossé D et al. Comprehensive meta-analysis of key immune-related adverse events from CTLA-4 and PD-1/PD-L1 inhibitors in cancer patients. Cancer Immunol Res. 2017 Feb 28. pii: canimm.0237.2016.
Nishijima TF, Shachar SS, Nyrop KA et al. Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis. Oncologist. 2017 Mar 8. pii: theoncologist.2016-0419.
Citation tools
González Vázquez S, de la Riva Onandía S, Echeveste J, Muñoz Navas M. Immune mediated colitis caused by lung cancer treatment with atezolizumab. 5060/2017


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 848 visits.
This article has been downloaded 251 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 17/05/2017

Accepted: 22/06/2017

Online First: 11/10/2017

Published: 04/12/2017

Article revision time: 33 days

Article Online First time: 147 days

Article editing time: 201 days


Share
This article has been rated by 4 readers.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2023 y Creative Commons. The Spanish Journal of Gastroenterology